New Treatment Guidelines for Non-Alcoholic Fatty Liver Disease Unveiled | The 4 Pillar Report

New Treatment Guidelines for Non-Alcoholic Fatty Liver Disease Unveiled

Health authorities have announced the integration of top-ranked therapies for non-alcoholic fatty liver disease (NAFLD) into treatment guidelines, including aldafermin and pegozafermin. Supported by strong evidence on MRI-PDFF reduction at 24 weeks, this consensus signals a low-risk posture for these interventions, paving the way for implementation planning among stakeholders. This decisive action marks a significant advancement in managing NAFLD, potentially transforming patient outcomes.

Week 29

New Treatment Guidelines for Non-Alcoholic Fatty Liver Disease Unveiled

PILLAR DIAGNOSTIC // WEEK 29

Confidence 90%

“The assembled evidence from the machine‐learning pillar yields a consistent SUCRA ranking for MRI‐PDFF reduction at 24 weeks, with no conflicting claims identified. This consensus supports a low risk posture, indicating reliable guidance for clinical decision‐making around these interventions.”

Proposed action

Proceed to integrate the top‐ranked therapies (aldafermin, pegozafermin, pioglitazone, efinopegdutide, semaglutide + firsocostat, and pegbelfermin) into treatment guidelines and advance to stakeholders for implementation planning.

THE MECHANICS

Spread & delivery

—

THE MACHINE

Evidence & systems

—

Aldafermin, pegozafermin, and pioglitazone top SUCRA rankings for MRI-PDFF reduction at 24 weeks, while efinopegdutide, semaglutide plus firsocostat, and pegbelfermin lead in achieving at least a 30% decline over the same period.

THE MAP

Policy & population

—

THE MOOD

Trust & behavior

—

Week 29

Confidence: 90%

The assembled evidence from the machine‐learning pillar yields a consistent SUCRA ranking for MRI‐PDFF reduction at 24 weeks, with no conflicting claims identified. This consensus supports a low risk posture, indicating reliable guidance for clinical decision‐making around these interventions.

Mechanics

Spread & delivery

Operational layer: transmission pathways, care delivery, supply chains, and how burden moves through systems.

—

No sources

Machine

Evidence & systems

Institutional and clinical bedrock: trials, standards, staffing, capacity, and what the evidence supports.

Audit trail active

The Map

Policy & population

Boundary layer: regulators, jurisdiction, access, demographics, and rules that bound what is possible.

—

No sources

Mood

Trust & behavior

Human response: public trust, compliance, fear or fatigue, and how sentiment shapes real-world uptake.

—

No sources